COVID-19 Update #21 - April 27 - Information for residency programs, message from CIHR and new research opportunity

This is the 21st update to the Schulich Medicine & Dentistry community.

This update includes information about:

    1. Information for residency program

    2. Update from CIHR

You can now access all these updates online . You can also continue to access the Travel, Education and Visitor Policy , the COVID-19 Travel Reimbursement Policy and the status of our education and research programs online.

Information for residency programs

Update from CIHR

In a recent message from Dr. Michael Strong, he shared information about funding for trainees and the launch of May 2020 COVID-19 Rapid Research Response Funding Opportunity. Information on funding opportunity shared below. 

      • Application Deadline: May 11, 2020
      • Total Funding Available for Competition: $107.9 million (see additional details in funding opportunity re: breakdown)
      • Budget and Duration: Maximum $5 million for clinical trial research over one year; maximum $2.5 million for all other types of research
      • Budget amounts have been set at these levels to allow for adequate funding of some of the research that could be submitted. However, it is expected that most budgets will be significantly lower than these maximums.
      • Research Areas: Will provide funding for clinical trials, including pragmatic and adaptive trials in addition to amplification of existing trials, trial networks or platforms to include COVID-19 data elements. This can include the inclusion of Canadian sites for trials being led or funded internationally.
      • Funding is also available for observational studies, implementation science or other relevant study designs to scale-up promising existing projects, reorient current research or platforms, or initiate new rapid response research that can be initiated immediately upon successful application of funds, to address COVID-19 in one of more of the following research areas.
      • Understanding the safety, efficacy, effectiveness, ethics, and implementation of: Vaccines, diagnostics, or therapeutics; Clinical management and health system interventions conditions; Social, policy and public health responses and related indirect consequences.
      • See funding announcement for examples in each area.
      • Proposals are encouraged to consider priority populations that may face unique contexts and/or challenges including: older adults, children and their families, homeless and under-housed populations, populations living in institutional or communal settings (including long term care facilities), immune compromised citizens and/or those living with serious chronic conditions, those who face unintended systematic bias(es) within the health care system, First Nations, Inuit and Métis communities, populations living in remote settings, refugees, people in countries with weaker health systems.
      • Sex and gender differences exist in the research areas above, making sex and/or gender issues an important component of this research initiative. CIHR will require applicants to consider sex as a biological variable and gender as a socio-cultural factor in their research.

Please send ALL communication related to the COVID-19 pandemic that you need to be shared with the Schulich Medicine & Dentistry community for faculty, staff, students, learners, trainees and fellows to Jennifer Parraga. The information will be compiled and shared with the School.

Helpful links